Immunotherapies in Huntington's disease and α-Synucleinopathies
Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no ef...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00337/full |
id |
doaj-fc20c1af572b4193b1b52d2dde1c3273 |
---|---|
record_format |
Article |
spelling |
doaj-fc20c1af572b4193b1b52d2dde1c32732020-11-25T02:38:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-02-011110.3389/fimmu.2020.00337517415Immunotherapies in Huntington's disease and α-SynucleinopathiesOluwaseun Fatoba0Oluwaseun Fatoba1Yosuke Ohtake2Yosuke Ohtake3Takahide Itokazu4Takahide Itokazu5Toshihide Yamashita6Toshihide Yamashita7Toshihide Yamashita8Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, JapanWPI -Immunology Frontier Research Center, Osaka University, Suita, JapanDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, JapanDepartment of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, JapanDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, JapanDepartment of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, JapanDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, JapanWPI -Immunology Frontier Research Center, Osaka University, Suita, JapanDepartment of Neuro-Medical Science, Graduate School of Medicine, Osaka University, Suita, JapanModulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no efficacy in alleviating disease burden and restoring functional capacity. Marked immune system activation and neuroinflammation are important features and prodromal signs in polyQ repeat disorders and α-synucleinopathies. This review describes the current status and future directions of immunotherapies in proteinopathy-induced neurodegeneration with emphasis on preclinical and clinical efficacies of several anti-inflammatory compounds and antibody-based therapies for the treatment of Huntington's disease and α-synucleinopathies. The review concludes with how disease modification and functional restoration could be achieved by using targeted multimodality therapy to target multiple factors.https://www.frontiersin.org/article/10.3389/fimmu.2020.00337/fullHuntington's diseaseα-synucleinopathiesimmune activationimmunotherapycombination therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Oluwaseun Fatoba Oluwaseun Fatoba Yosuke Ohtake Yosuke Ohtake Takahide Itokazu Takahide Itokazu Toshihide Yamashita Toshihide Yamashita Toshihide Yamashita |
spellingShingle |
Oluwaseun Fatoba Oluwaseun Fatoba Yosuke Ohtake Yosuke Ohtake Takahide Itokazu Takahide Itokazu Toshihide Yamashita Toshihide Yamashita Toshihide Yamashita Immunotherapies in Huntington's disease and α-Synucleinopathies Frontiers in Immunology Huntington's disease α-synucleinopathies immune activation immunotherapy combination therapy |
author_facet |
Oluwaseun Fatoba Oluwaseun Fatoba Yosuke Ohtake Yosuke Ohtake Takahide Itokazu Takahide Itokazu Toshihide Yamashita Toshihide Yamashita Toshihide Yamashita |
author_sort |
Oluwaseun Fatoba |
title |
Immunotherapies in Huntington's disease and α-Synucleinopathies |
title_short |
Immunotherapies in Huntington's disease and α-Synucleinopathies |
title_full |
Immunotherapies in Huntington's disease and α-Synucleinopathies |
title_fullStr |
Immunotherapies in Huntington's disease and α-Synucleinopathies |
title_full_unstemmed |
Immunotherapies in Huntington's disease and α-Synucleinopathies |
title_sort |
immunotherapies in huntington's disease and α-synucleinopathies |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-02-01 |
description |
Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no efficacy in alleviating disease burden and restoring functional capacity. Marked immune system activation and neuroinflammation are important features and prodromal signs in polyQ repeat disorders and α-synucleinopathies. This review describes the current status and future directions of immunotherapies in proteinopathy-induced neurodegeneration with emphasis on preclinical and clinical efficacies of several anti-inflammatory compounds and antibody-based therapies for the treatment of Huntington's disease and α-synucleinopathies. The review concludes with how disease modification and functional restoration could be achieved by using targeted multimodality therapy to target multiple factors. |
topic |
Huntington's disease α-synucleinopathies immune activation immunotherapy combination therapy |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2020.00337/full |
work_keys_str_mv |
AT oluwaseunfatoba immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT oluwaseunfatoba immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT yosukeohtake immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT yosukeohtake immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT takahideitokazu immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT takahideitokazu immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT toshihideyamashita immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT toshihideyamashita immunotherapiesinhuntingtonsdiseaseandasynucleinopathies AT toshihideyamashita immunotherapiesinhuntingtonsdiseaseandasynucleinopathies |
_version_ |
1724789935812116480 |